Changes in serum levels of prostatic acid phosphatase and prostate specific antigen after luteinizing hormone-releasing hormone analogue administration in patients with metastatic prostatic cancer in relation to glandular differentiation

• Published in: International urology and nephrology Vol. 27; no. 6; p. 769
• Main Authors: Sasagawa, I, Nakada, T, Kubota, Y, Sawamura, T, Izumiya, K
• Format: Journal Article
• Language: English
• Published: Netherlands 01.11.1995
• Subjects: Acid Phosphatase - blood; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal - therapeutic use; Humans; Leuprolide - therapeutic use; Luteinizing Hormone - blood; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent - blood; Neoplasms, Hormone-Dependent - drug therapy; Neoplasms, Hormone-Dependent - pathology; Prognosis; Prostate - enzymology; Prostate-Specific Antigen - blood; Prostatic Neoplasms - blood; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - pathology; Testosterone - blood
• ISSN: 0301-1623
• DOI: 10.1007/BF02552145

Eighteen previously untreated patients with metastatic carcinoma of the prostate were treated with LHRH analogue. They were divided into 3 groups according to the degree of glandular differentiation. In all groups, a transient rise of PAP and PSA was observed after the LH and testosterone surge. However, relative values of LH, testosterone, PAP and PSA did not differ significantly among the 3 groups. These facts suggest that a transient rise of PAP and PSA is caused by testosterone surge independently from the degree of glandular differentiation after LHRH analogue administration in patients with advanced prostatic cancer.